

Sofiva Genomics Co Ltd. and Subsidiaries
Consolidated Financial Statements for the Three Months Ended
September 30, 2025 and 2024 and Independent Auditors' Report
(Stock Code: 6615)

Company Address: 4F.-2, No. 66-1, Sec. 1, Chongqing S. Rd.,
Zhongzheng Dist., Taipei City

Telephone: (02)2382-6615

Sofiva Genomics Co. Ltd. and Subsidiaries
Consolidated Financial Statements for the Three Months Ended September 30, 2025 and
Independent Auditors' Report
Contents

<u>item</u>	<u>Head</u>	<u>Page</u>
I. Cover		1
II. Table of Contents		2 ~ 3
III. Auditor's Review Report		4 ~ 5
IV. Consolidated Balance Sheet		6 ~ 7
V. Consolidated Income Statement		8
VI. Consolidated Statement of Changes in Equity		9
VII. Consolidated Cash Flow Statement		10
VIII. Notes to the Consolidated Financial Statements		11 ~ 49
(I) Company History		11
(ii) Date and procedure for submitting financial statements		11
(III) Application of Newly Issued and Revised Guidelines and Interpretations		11 ~ 13
(iv) Summary of significant accounting policies		13 ~ 21
(v) Major sources of uncertainty in significant accounting judgments, estimates and assumptions		22
(vi) Explanation of Important Accounting Items		22 ~ 39
(vii) Transactions with related parties		40 ~ 42

<u>item</u>	<u>Head</u>	<u>Page</u>
(viii) Pledged Assets		42
(ix) Material contingent liabilities and unrecognized contractual commitments		42
(x) Major disaster losses		42
(xi) Major Subsequent Events		42
(xii) Other		43 ~ 48
(xiii) Matters disclosed in the notes		48 ~ 49
(XIV) Departmental Information		49

Independent Auditors' Review Report

(114) Cai-Shen-Bao-Zi No. 25002303

To the Board of Directors of

Sofiva Genomics Co., Ltd.:

Introduction

We have reviewed the accompanying consolidated balance sheets of **Sofiva Genomics Co., Ltd. and its subsidiaries** as of **September 30, 2025 and 2024**, the related consolidated statements of comprehensive income for the **three-month and nine-month periods ended September 30, 2025 and 2024**, and the consolidated statements of changes in equity and cash flows for the **nine-month periods ended September 30, 2025 and 2024**, as well as the accompanying notes to the consolidated financial statements (including a summary of significant accounting policies).

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the **Regulations Governing the Preparation of Financial Reports by Securities Issuers** and **International Accounting Standard 34, "Interim Financial Reporting,"** as endorsed and issued by the **Financial Supervisory Commission of the Republic of China**. Our responsibility is to express a conclusion on the consolidated financial statements based on our review.

Scope

Except as described in the **Basis for Qualified Conclusion** section, we conducted our review in accordance with **Statement of Review Engagements No. 2410, "Review of Financial Statements,"** of the Republic of China. A review of consolidated financial statements consists of inquiries, primarily of persons responsible for financial and accounting matters, analytical procedures, and other review procedures. A review is substantially less in scope than an audit conducted in accordance with auditing standards generally accepted in the Republic of China and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Basis for Qualified Conclusion

As described in Notes **4(3)** and **6(4)** to the consolidated financial statements, the financial statements of non-significant subsidiaries and investments accounted for

using the equity method included in the consolidated financial statements for the same periods were **not reviewed by auditors**.

As of **September 30, 2025 and 2024**, the total assets (including investments accounted for using the equity method) of such entities amounted to **NT\$416,067 thousand** and **NT\$412,129 thousand**, representing **57.19%** and **53.08%** of the consolidated total assets, respectively; total liabilities amounted to **NT\$8,705 thousand** and **NT\$15,285 thousand**, representing **9.17%** and **11.96%** of the consolidated total liabilities, respectively.

For the **three-month periods ended September 30, 2025 and 2024**, and the **nine-month periods ended September 30, 2025 and 2024**, the total comprehensive income (loss) (including the share of comprehensive income (loss) of investments accounted for using the equity method) amounted to **NT\$6,452 thousand**, **NT\$6,713 thousand**, **NT\$22,022 thousand**, and **NT\$23,459 thousand**, representing **(516.57%)**, **428.13%**, **(457.08%)**, and **98.60%** of the consolidated total comprehensive income (loss), respectively.

Qualified Conclusion

Based on our review, except for the possible effects of adjustments, if any, that might have been required had the financial statements of the non-significant subsidiaries and investments accounted for using the equity method for the same periods been reviewed by auditors as described in the **Basis for Qualified Conclusion** section, we are not aware of any material modifications that should be made to the accompanying consolidated financial statements in order for them to be prepared, in all material respects, in accordance with the **Regulations Governing the Preparation of Financial Reports by Securities Issuers** and **International Accounting Standard 34, "Interim Financial Reporting,"** as endorsed and issued by the **Financial Supervisory Commission of the Republic of China**, so as to fairly present the consolidated financial position of **Sofiva Genomics Co., Ltd. and its subsidiaries** as of **September 30, 2025 and 2024**, and their consolidated financial performance for the **three-month and nine-month periods ended September 30, 2025 and 2024**, and their consolidated cash flows for the **nine-month periods ended September 30, 2025 and 2024**.

PwC Taiwan

Chih-Fan Yu, CPA

Ping-Chun Chih, CPA

Approval No. Jin-Guan-Zheng-Shen-Zi No. 1110349013
Financial Supervisory Commission, Republic of China
Former Securities and Futures Bureau, Ministry of Finance
Approval No. (88) Tai-Cai-Zheng (6) No. 16120
November 12, 2025
Republic of China

Sofiva Genomics Co. Ltd. and Subsidiaries

Consolidated Balance Sheets

March 31, 2025, December 31, 2024 and September 30, 2024

(The consolidated balance sheets as of March 31, 2025 and 2024 are reviewed, not audited in conformity with the ROC GAAS)
(Expressed in thousands of New Taiwan dollars)

assets		Notes	September 30, 114		December 31, 113		September 30, 113	
			A m o u n t	%	A m o u n t	%	A m o u n t	%
Current assets								
1100	Cash and cash equivalents	6(1)	\$ 76,537	11	\$ 112,079	15	\$ 102,083	13
1136	Financial assets measured at	6(1)						
	amortized cost - Current		34,100	5	34,100	4	34,100	4
1140	Contractual Assets - Liquidity	6 (14) and 7						
		(two)	5,894	1	9,410	1	9,317	1
1150	Net amount of notes receivable	6(2)	1,846	-	2,508	-	3,109	1
1170	Net accounts receivable	6(2)	52,409	7	51,431	7	54,968	7
1180	Accounts Receivable - Net Amount	6 (2) and 7						
	from Related Parties	(two)	2,048	-	2,590	-	2,814	-
1220	Current period income tax assets	6 (19)	3,828	1	4,979	1	4,506	1
130X	stock	6(3)	45,164	6	46,397	6	51,361	7
1410	Prepayment		10,988	1	7,954	1	12,590	2
1470	Other current assets		1,060	-	1,152	-	1,176	-
11XX	Total current assets		<u>233,874</u>	<u>32</u>	<u>272,600</u>	<u>35</u>	<u>276,024</u>	<u>36</u>
Non-current assets								
1550	Equity method investment	6(4)	381,176	52	368,015	48	361,553	47
1600	Real estate, plant and equipment	6 (5)	40,601	6	53,160	7	57,869	7
1755	Right of use assets	6(6)	35,803	5	49,996	7	54,025	7
1780	Intangible assets		7,424	1	8,192	1	8,578	1
1840	Deferred tax assets		4,719	1	5,061	1	7,212	1
1920	Deposit margin		10,467	1	11,059	1	11,230	1
1990	Other non-current assets - others		13,466	2	-	-	-	-
15XX	Total non-current assets		<u>493,656</u>	<u>68</u>	<u>495,483</u>	<u>65</u>	<u>500,467</u>	<u>64</u>
1XXX	Total assets		<u>\$ 727,530</u>	<u>100</u>	<u>\$ 768,083</u>	<u>100</u>	<u>\$ 776,491</u>	<u>100</u>

(Continued on next page)

Sofiva Genomics Co. Ltd. and Subsidiaries

Consolidated Balance Sheets

March 31, 2025, December 31, 2024 and September 30, 2024

(The consolidated balance sheets as of March 31, 2025 and 2024 are reviewed, not audited in conformity with the ROC GAAS)
(Expressed in thousands of New Taiwan dollars)

Liabilities and Equity		Notes	September 30, 114		December 31, 113		September 30, 113	
			A m o u n t	%	A m o u n t	%	A m o u n t	%
Liabilities								
Current liabilities								
2130	Contractual Liabilities - Current	6(14)	\$ 798	-	\$ 1,773	-	\$ 2,175	-
2170	Accounts Payable		16,099	2	19,256	3	21,385	3
2180	Accounts Payable - Related Parties	7(2)	2,933	1	3,216	1	3,985	-
2200	Other payables	6 (7) and 7						
		(two)	30,328	4	40,773	5	36,663	5
2230	Current period income tax liabilities	6 (19)	960	-	-	-	234	-
2250	Liability Provisions - Current	6 (8)	716	-	1,060	-	1,144	-
2280	Lease liabilities - current		13,831	2	16,428	2	16,339	2
2300	Other current liabilities		961	-	951	-	1,420	-
21XX	Total current liabilities		<u>66,626</u>	<u>9</u>	<u>83,457</u>	<u>11</u>	<u>83,345</u>	<u>10</u>
Non-current liabilities								
2550	Provision for liabilities - non-current	6 (8)	3,064	-	3,030	-	3,019	1
2570	Deferred tax liabilities		155	-	238	-	368	-
2580	Lease liabilities - non-current		25,132	4	36,954	5	41,095	5
25XX	Total non-current liabilities		<u>28,351</u>	<u>4</u>	<u>40,222</u>	<u>5</u>	<u>44,482</u>	<u>6</u>
2XXX	Total Liabilities		<u>94,977</u>	<u>13</u>	<u>123,679</u>	<u>16</u>	<u>127,827</u>	<u>16</u>
Rights belonging to the parent company's owners								
	Share capital	6(11)						
3110	Common stock capital		215,934	30	215,934	28	215,934	28
	Capital Reserve	6 (12)						
3200	Capital Reserve		341,589	47	341,594	44	341,074	44
	Retained Earnings	6 (13)						
3310	Statutory surplus reserve		37,481	5	35,638	5	35,638	5
3320	Special surplus reserve		148	-	46	-	46	-
3350	Undistributed surplus		37,731	5	50,978	7	56,336	7
	Other rights							
3400	Other rights		(126)	-	(148)	-	(169)	-
31XX	Total equity attributable to		<u>632,757</u>	<u>87</u>	<u>644,042</u>	<u>84</u>	<u>648,859</u>	<u>84</u>

後附合併財務報表附註為本合併財務報告之一部分，請併同參閱。

董事長:蘇怡寧

經理人:洪加政

會計主管:張伏見

Sofiva Genomics Co. Ltd. and Subsidiaries

Consolidated Balance Sheets

March 31, 2025, December 31, 2024 and September 30, 2024

(The consolidated balance sheets as of March 31, 2025 and 2024 are reviewed, not audited in conformity with the ROC GAAS)
(Expressed in thousands of New Taiwan dollars)

	owners of the parent company									
36XX	Non-controlling interests	(<u>204</u>)	-	<u>362</u>	-	(<u>195</u>)	-		
3XXX	Total equity		<u>632,553</u>	<u>87</u>	<u>644,404</u>	<u>84</u>	<u>648,664</u>	<u>84</u>		
	Significant contingent liabilities and unrecognized contractual commitments			Nine						
	Post-major events			eleven						
3X2X	Total liabilities and equity	\$	<u>727,530</u>	<u>100</u>	\$	<u>768,083</u>	<u>100</u>	\$	<u>776,491</u>	<u>100</u>

後附合併財務報表附註為本合併財務報告之一部分，請併同參閱。

董事長:蘇怡寧

經理人:洪加政

會計主管:張伏見

Sofiva Genomics Co. Ltd. and Subsidiaries

Consolidated Statements of Comprehensive Income

For the Three Months Ended September 30, 2025 and 2024

(Expressed in thousands of New Taiwan dollars,
except for earnings per share amount)

	project	Notes	July 1, 114 Until September 3 0		July 1, 113 Until September 3 0		January 1, 114 Until September 3 0		January 1, 113 Until September 3 0	
			A m o u n t	%	A m o u n t	%	A m o u n t	%	A m o u n t	%
4000	Operating revenue	6 (14) and 7 (2)	\$ 93,411	100	\$ 106,249	100	\$ 290,013	100	\$ 349,842	100
5000	Operating costs	6 (3) (17) and 7 (two)	(68,397)	(73)	(78,305)	(74)	(213,560)	(73)	(241,304)	(69)
5900	Gross profit		25,014	27	27,944	26	76,453	27	108,538	31
	Operating expenses	6 (17) and 7 (2)								
6100	Sales expenses		(10,545)	(11)	(14,292)	(14)	(36,320)	(12)	(38,464)	(11)
6200	Management expenses		(17,086)	(18)	(19,104)	(18)	(56,769)	(20)	(58,409)	(16)
6300	Research and development expenses		(2,351)	(3)	(1,527)	(1)	(7,715)	(3)	(6,496)	(2)
6450	Expected credit impairment gains (losses)	12 (II)	-	-	-	-	1	-	(4)	-
6000	Total operating expenses		(29,982)	(32)	(34,923)	(33)	(100,803)	(35)	(103,373)	(29)
6900	Operating profit (loss)		(4,968)	(5)	(6,979)	(7)	(24,350)	(8)	(5,165)	(2)
	Non-operating income and expenses									
7100	Interest income	6 (15)	252	-	245	-	1,000	-	988	-
7010	Other income		1,497	2	472	1	1,700	1	798	-
7020	Other benefits and losses		355	-	1,003	1	(447)	-	785	-
7050	Financial costs	6 (16)	(197)	-	(284)	-	(670)	-	(846)	-
7060	Shares of profits and losses of related parties and joint ventures recognized using the equity method	6(4)	5,951	6	6,573	6	19,091	6	19,391	6
7000	Total non-operating income and expenses		7,858	8	8,009	8	20,674	7	21,116	6
7900	Pre-tax net profit (net loss)		2,890	3	1,030	1	(3,676)	(1)	26,281	8
7950	Income tax (expense) benefits	6 (19)	(4,073)	(4)	722	-	(1,167)	(1)	(2,349)	(1)
8200	Net profit (net loss) for this period		(\$ 1,183)	(1)	\$ 1,752	1	(\$ 4,843)	(2)	\$ 23,932	7
	Other comprehensive income and loss									
	Items that may be reclassified to profit or loss in the future									
8361	Exchange differences in the translation of financial statements of foreign operating entities		(\$ 80)	-	(\$ 224)	-	\$ 31	-	(\$ 171)	-

後附合併財務報表附註為本合併財務報告之一部分，請併同參閱。

董事長:蘇怡寧

經理人:洪加政

會計主管:張伏見

(Expressed in thousands of New Taiwan dollars,
except for earnings per share amount)

後附合併財務報表附註為本合併財務報告之一部分，請併同參閱。

會計主管：張伏見

Sofiva Genomics Co. Ltd. and Subsidiaries
Consolidated Statements of Changes in Equity
For the three months ended September 30, 2025 and 2024
(Reviewed, not audited in conformity with the ROC GAAS)

(Expressed in thousands of New Taiwan dollars)

	R i g h t s b e l o n g i n g t o t h e p a r e n t c o m p a n y ' s o w n e r s											
	C a p i t a l	R e s e r v e	R e t a i n e d	E a r n i n g s	O t h e r r i g h t s							
			Related Party Recognition Using the Equity Method Changes in corporate net equity	Employee Stock Options		Statutory surplus reserve	Special surplus reserve	Undistributed surplus	Difference in Table Conversion		Non-controlling interests	
N o t e s	C o m m o n s t o c k c a p i t a l	I s s u a n c e p r e m i u m	D y n a m i c s	O p t i o n s	o t h e r	s u r p l u s r e s e r v e	r e s e r v e	s u r p l u s	C o n v e r s i o n	t o t a l	i n t e r e s t s	t o t a l
<u>January 1 to September 30, 113</u>												
Balance as of January 1, 113	\$ 213,624	\$ 225,173	\$ 98,456	\$ 8,319	\$ 112	\$ 34,485	\$ 32	\$ 37,987	(\$ 46)	\$ 618,142	\$ 230	\$ 618,372
Net profit for this period	-	-	-	-	-	-	-	23,788	-	23,788	144	23,932
Other comprehensive (profit and loss) in this period	-	-	-	-	-	-	-	-	(123)	(123)	(18)	(141)
Total comprehensive (profit) and loss for this period	-	-	-	-	-	-	-	23,788	(123)	23,665	126	23,791
2012 Earnings Allocation and Distribution 6 (13)												
Appropriation of statutory surplus reserve	-	-	-	-	-	1,153	- (1,153)	-	-	-	-	-
Special surplus reserve	-	-	-	-	-	-	14 (14)	-	-	-	-	-
Cash dividends on common stock	-	-	-	-	-	-	- (4,272)	-	(4,272)	-	(4,272)	-
Employee Stock Option Compensation Cost sixty)	-	-	- (742)	-	-	-	-	-	(742)	-	(742)	-
Employee stock options expire sixty)	-	-	- (318)	318	-	-	-	-	-	-	-	-
Employee exercise of stock options sixty)	2,310	12,320	- (2,564)	-	-	-	-	-	-	12,066	-	12,066
Increase or decrease of non-controlling interests 4 (3)	-	-	-	-	-	-	-	-	-	-	(551)	(551)
Balance as of September 30, 113	\$ 215,934	\$ 237,493	\$ 98,456	\$ 4,695	\$ 430	\$ 35,638	\$ 46	\$ 56,336	(\$ 169)	\$ 648,859	(\$ 195)	\$ 648,664
<u>January 1 to September 30, 114</u>												
Balance as of January 1, 114	\$ 215,934	\$ 237,493	\$ 98,961	\$ 4,710	\$ 430	\$ 35,638	\$ 46	\$ 50,978	(\$ 148)	\$ 644,042	\$ 362	\$ 644,404
Net loss for this period	-	-	-	-	-	-	-	(4,824)	-	(4,824)	(19)	(4,843)
Other comprehensive (profit and loss) in this period	-	-	-	-	-	-	-	-	twenty two	twenty two	3	25
Total comprehensive (profit) and loss for this period	-	-	-	-	-	-	-	(4,824)	twenty two	(4,802)	(16)	(4,818)
113 Year Surplus Allocation and 6 (13)												

後附合併財務報表附註為本合併財務報告之一部分，請併同參閱。

董事長：蘇怡寧

經理人：洪加政

會計主管：張伏見

Sofiva Genomics Co. Ltd. and Subsidiaries
Consolidated Statements of Changes in Equity
For the three months ended September 30, 2025 and 2024
(Reviewed, not audited in conformity with the ROC GAAS)

(Expressed in thousands of New Taiwan dollars)

		R i g h t s b e l o n g i n g t o t h e p a r e n t c o m p a n y ' s o w n e r s											
		C a p i t a l	R e s e r v e	R e t a i n e d	E a r n i n g s							Other rights	
				Related Party Recognition Using the Equity Method	Changes in corporate net equity	Employee Stock Options	Statutory surplus reserve	Special surplus reserve	Undistributed surplus	Difference in Table Exchange	Conversion	Non-controlling interests	
N o t e s		c a p i t a l	I s s u a n c e p r e m i u m	D y n a m i c s	O p t i o n s	o t h e r	s u r p l u s r e s e r v e	r e s e r v e	s u r p l u s	C o n v e r s i o n	t o t a l	i n t e r e s t s	t o t a l
Distribution													
Appropriation of statutory surplus reserve		-	-	-	-	-	1,843	-	(1,843)	-	-	-	-
Special surplus reserve		-	-	-	-	-	-	102	(102)	-	-	-	-
Cash dividends on common stock		-	-	-	-	-	-	-	(6,478)	-	(6,478)	-	(6,478)
Employee Stock Option Compensation Cost	sixty)	-	-	-	(5)	-	-	-	-	-	(5)	-	(5)
Employee stock options expire	sixty)	-	-	-	(4,382)	4,382	-	-	-	-	-	-	-
Increase or decrease of non-controlling interests	4 (3)	-	-	-	-	-	-	-	-	-	-	(550)	(550)
Balance as of September 30, 114		<u>\$ 215,934</u>	<u>\$ 237,493</u>	<u>\$ 98,961</u>	<u>\$ 323</u>	<u>\$ 4,812</u>	<u>\$ 37,481</u>	<u>\$ 148</u>	<u>\$ 37,731</u>	<u>(\$ 126)</u>	<u>\$ 632,757</u>	<u>(\$ 204)</u>	<u>\$ 632,553</u>

後附合併財務報表附註為本合併財務報告之一部分，請併同參閱。

董事長：蘇怡寧

經理人：洪加政

會計主管：張伏見

Sofiva Genomics Co. Ltd. and Subsidiaries
Consolidated Statements of Cash Flows
For the three months ended September 30, 2025 and 2024
(Reviewed, not audited in conformity with the ROC GAAS)

(Expressed in thousands of New Taiwan dollars)

	Notes	January 1, 114 Until September 3 0 t h	January 1, 113 Until September 3 0 t h
Cash flow from operating activities			
Pre-tax (net loss) net profit for this period		(\$ 3,676)	\$ 26,281
Adjustment Project			
Revenue and expense items			
Depreciation expenses of real estate, plant and equipment and right-of-use assets	6(17)	25,388	26,490
Intangible asset amortization expense	6(17)	6,474	4,646
Expected credit impairment loss (or gain)	12 (II)	(1)	4
Interest expenses	6 (16)	670	846
Interest income	6 (15)	(1,000)	(988)
Employee Stock Option Compensation Cost	sixty)	(5)	(742)
Share of related party profit (or loss) recognized using the equity method	6(4)	(19,091)	(19,391)
Losses or gains from the disposal of real estate, factory buildings, and equipment.		3	-
Lease modification of profit (loss)		(31)	-
Changes in assets/liabilities related to operating activities			
Net changes in assets related to operating activities			
Contractual Assets - Liquidity		3,516	(5,158)
Net amount of notes receivable		662	3,801
Net accounts receivable		(977)	5,204
Accounts Receivable - Net Amount from Related Parties		542	1,886
Other receivables		-	612
stock		1,233	(9,574)
Prepayment		(3,034)	(3,814)
Other current assets		92	614
Net change in liabilities related to operating activities			
Contractual Liabilities - Current		(975)	1,402
Accounts Payable		(3,157)	(5,562)
Accounts Payable - Related Parties		(283)	(785)
Other payables		(10,049)	(7,525)
Liability Provisions - Current		(344)	(1,321)
Other current liabilities		10	(208)
Provision for liabilities - non-current		-	(197)
Cash inflows from operations (outflows)		(4,033)	16,521
Interest collected		1,000	988
Interest paid		(636)	(812)
Income tax collected		5,003	7,856
Income tax paid		(3,813)	(3,766)
Net cash inflow from operating activities		(2,479)	20,787
Cash flows from investing activities			
Financial assets measured at amortized cost - Decrease in current assets		-	9,125
Acquisition of real estate, plant and equipment	6 (21)	(358)	(16,801)
Disposal of real estate, factory buildings and equipment		41	-
Acquisition of intangible assets	6 (21)	(6,995)	(7,249)

後附合併財務報表附註為本合併財務報告之一部分，請併同參閱。

董事長:蘇怡寧

經理人:洪加政

會計主管:張伏見

Sofiva Genomics Co. Ltd. and Subsidiaries
Consolidated Statements of Cash Flows
For the three months ended September 30, 2025 and 2024
(Reviewed, not audited in conformity with the ROC GAAS)

(Expressed in thousands of New Taiwan dollars)

	Notes	January 1, 114 Until September 3 0 t h	January 1, 113 Until September 3 0 t h
Other non-current assets increased		(13,466)	-
Increase in margin deposits		(163)	(5,821)
Decrease in margin deposits		755	4,044
Dividends received		5,930	5,930
Net cash outflow from investing activities		(14,256)	(10,772)
<u>Cash flows from financing activities</u>			
Lease liability principal repayment	6 (22)	(11,817)	(11,757)
Cash dividends	6 (22)	(6,478)	(4,272)
Employee exercise of stock options		-	12,066
Changes in non-controlling equity	4(3)	(550)	(551)
Net cash outflow from financing activities		(18,845)	(4,514)
Exchange rate impact		38	(224)
Cash and cash equivalents (decrease) increased during the period		(35,542)	5,277
Beginning cash and cash equivalents	6(1)	112,079	96,806
Cash and cash equivalents at the end of the period	6(1)	<u>\$ 76,537</u>	<u>\$ 102,083</u>

後附合併財務報表附註為本合併財務報告之一部分，請併同參閱。

董事長:蘇怡寧

經理人:洪加政

會計主管:張伏見

Sofiva Genomics Co., Ltd. and Subsidiaries
Notes to the Consolidated Financial Statements
For the Three Months Ended September 30, 2025 and 2024
(Reviewed, not audited in conformity with the ROC GAAS)
(Expressed in thousands of New Taiwan dollars,
unless otherwise specified)

I. Company History

(1)

Sofiva Genomics Co., Ltd. (the “Company”) was incorporated on June 15, 2012 under the Company Act of the Republic of China (“R.O.C.”) and commenced operations thereafter. The Company and its subsidiaries (collectively, the “Group”) are principally engaged in providing genetic testing and medical testing services, including preconception, prenatal, and neonatal testing services.

(2)

In January 2017, the Company applied to the Taipei Exchange (“TPEX”), a subsidiary of the Securities and Futures Institute, for the listing of its common shares on the Emerging Stock Board, and its common shares have been traded on the TPEX since January 22, 2018.

II. Date and Procedures of Financial Statements Approval

These consolidated financial statements were approved for issuance by the Board of Directors on November 12, 2025.

III. Application of Newly Issued, Revised and Amended Standards and Interpretations

(1) The impact of the amendments to IFRSs as endorsed and issued into effect by the Financial Supervisory Commission (“FSC”)

The following table summarizes the newly issued, revised and amended International Financial Reporting Standards, International Accounting Standards, IFRIC Interpretations and SIC Interpretations (collectively, “IFRSs”) endorsed by the FSC and effective for the year 2025:

New / Amended Standards and Interpretations	Effective Date Issued by IASB
Amendments to IAS 21 “Lack of Exchangeability”	January 1, 2025

The Group has assessed the above standards and interpretations and concluded that they have no material impact on the Group’ s consolidated financial position and consolidated financial performance.

(2) The impact of IFRSs issued by the FSC but not yet effective

The following table summarizes the newly issued, revised and amended IFRSs endorsed by the FSC and effective for the year 2026:

New / Amended Standards and Interpretations	Effective Date Issued by IASB
Amendments to IFRS 9 and IFRS 7 “Amendments to the Classification and Measurement of Financial Instruments”	January 1, 2026
Amendments to IFRS 9 and IFRS 7 “Contracts Referencing Nature-dependent Electricity”	January 1, 2026
IFRS 17 “Insurance Contracts”	January 1, 2023
Amendments to IFRS 17 “Insurance Contracts”	January 1, 2023
Amendments to IFRS 17 “Initial Application of IFRS 17 and IFRS 9—Comparative Information”	January 1, 2023
Annual Improvements to IFRS Accounting Standards—Volume 11	January 1, 2026

The Group has assessed the above standards and interpretations and concluded that they have no material impact on the Group’ s consolidated financial position and consolidated financial performance.

(3) The impact of IFRSs issued by the IASB but not yet endorsed by the FSC

The following table summarizes the newly issued, revised and amended IFRSs issued by the International Accounting Standards Board (“IASB”) but not yet incorporated into IFRSs endorsed by the FSC:

New / Amended Standards and Interpretations	Effective Date Issued by IASB
Amendments to IFRS 10 and IAS 28 “Sale or Contribution of Assets between an Investor and its Associate or Joint Venture”	To be decided by the IASB
IFRS 18 “Presentation and Disclosure in Financial Statements”	January 1, 2027 (Note)
IFRS 19 “Subsidiaries without Public Accountability: Disclosures”	January 1, 2027

Note: In a press release dated September 25, 2025, the FSC announced that publicly listed companies will apply IFRS 18 starting from fiscal year 2028. Entities that intend to early adopt IFRS 18 may elect to do so after IFRS 18 is endorsed by the FSC.

Except as described below, the Group has assessed the above standards and interpretations and concluded that they have no material impact on the Group’s consolidated financial position and consolidated financial performance. The relevant impacts will be disclosed when the assessment is completed.

IFRS 18 “Presentation and Disclosure in Financial Statements”

IFRS 18 replaces IAS 1, updates the structure of the statement of comprehensive income, introduces disclosures of management-defined performance measures, and strengthens principles applied to aggregation and disaggregation in the primary financial statements and the notes.

IV. Summary of Significant Accounting Policies

The principal accounting policies applied in the preparation of these consolidated financial statements are set out below. Unless otherwise stated, these policies have been consistently applied to all periods presented.

(1) Statement of compliance

These consolidated financial statements have been prepared in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and IAS 34 “Interim Financial Reporting” as endorsed and issued into effect by the FSC.

(2) Basis of preparation

1. These consolidated financial statements have been prepared under the historical cost convention.
2. The preparation of financial statements in conformity with IFRSs requires the use of certain critical accounting estimates. It also requires management to exercise its judgment in the process of applying

the Group' s accounting policies. Areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to the consolidated financial statements, are disclosed in Note V.

(3) Basis of consolidation

1. Principles of preparation of consolidated financial statements

(1) The consolidated financial statements include all subsidiaries. Subsidiaries are entities (including structured entities) controlled by the Group. The Group controls an entity when it is exposed, or has rights, to variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. Subsidiaries are consolidated from the date on which control is transferred to the Group and are deconsolidated from the date that control ceases.

(2) Intra-group transactions, balances and unrealized gains or losses are eliminated. Accounting policies of subsidiaries have been adjusted where necessary to ensure consistency with the policies adopted by the Group.

(3) Profit or loss and each component of other comprehensive income are attributed to the owners of the parent and to the non-controlling interests. Total comprehensive income is also attributed to the owners of the parent and to the non-controlling interests even if this results in the non-controlling interests having a deficit balance.

2. Subsidiaries included in the consolidated financial statements

Investor	Subsidiary	Nature of business	Shareholding % as of Sep. 30, 2025	Dec. 31, 2024	Sep. 30, 2024	Remarks
The Company	Qunzhi Genomics Co., Ltd.	Testing services	100%	100%	100%	Note 1 / Note 2
The Company	Sofiva Genomics Bangkok Co., Ltd.	Testing services	90%	90%	90%	Note 1
The Company	Sofiva Genomics Medical Laboratory	Testing services	–	–	–	Note 1 / Note 3
The Company	Sofiva Genomics Clinical Medical Laboratory	Testing services	–	–	–	Note 1 / Note 4

Note 1: These are not significant subsidiaries. The financial statements as of September 30, 2025 and September 30, 2024 were not reviewed by the auditors. The financial statements as of December 31, 2024 were audited by the Company' s auditors.

Note 2: On March 29, 2024, the board of directors approved a cash capital reduction of NT\$15,000, with the record date on April 1, 2024. After the capital reduction, the paid-in capital amounted to NT\$15,000.

Note 3: The laboratory was established in June 2021. Although the Company has no equity investment in the

laboratory, the Company has control over its financial, operating, and personnel policies; therefore, it is included in the consolidation. The laboratory distributed earnings of NT\$304 in March 2024, resulting in an impact on non-controlling interests of (NT\$304). The laboratory distributed earnings of NT\$302 in March 2025, resulting in an impact on non-controlling interests of (NT\$302).

Note 4: The laboratory was established in February 2022. Although the Company has no equity investment in the laboratory, the Company has control over its financial, operating, and personnel policies; therefore, it is included in the consolidation. The laboratory distributed earnings of NT\$247 in March 2024, resulting in an impact on non-controlling interests of (NT\$247). The laboratory distributed earnings of NT\$248 in March 2025, resulting in an impact on non-controlling interests of (NT\$248).

3. **Subsidiaries not included in the consolidated financial statements:** None.
4. **Adjustments for subsidiaries with different reporting periods:** None.
5. **Significant restrictions:** None.
6. **Subsidiaries with material non-controlling interests:** None.

(4) Foreign currency translation

Items included in the financial statements of each entity in the Group are measured using the currency of the primary economic environment in which the entity operates (the “functional currency”). The functional currency of the Company is the New Taiwan dollar (“NT\$”), and the functional currencies of the subsidiaries are NT\$ and Thai baht. These consolidated financial statements are presented in NT\$, which is the Company’s functional currency.

1. Foreign currency transactions and balances

- (1) Foreign currency transactions are translated into the functional currency using the spot exchange rate at the dates of the transactions or measurement dates. Foreign exchange gains and losses resulting from the settlement of such transactions are recognized in profit or loss.
- (2) Foreign currency monetary assets and liabilities are translated at the spot exchange rate at the balance sheet date. Exchange differences arising from such translation are recognized in profit or loss.
- (3) All foreign exchange gains and losses are presented in “Other gains and losses” in the consolidated statements of comprehensive income.

2. Translation of foreign operations

The results and financial position of all Group entities, associates and joint arrangements that have a functional currency different from the presentation currency are translated into the presentation currency as follows:

- (1) Assets and liabilities are translated at the closing rate at the date of each balance sheet.
- (2) Income and expenses are translated at average exchange rates for the period.
- (3) All resulting exchange differences are recognized in other comprehensive income.

(5) Classification of assets and liabilities as current and non-current

1. **Assets** are classified as current assets if they meet any of the following criteria:
 - (1) Expected to be realized in, or intended for sale or consumption in, the normal operating cycle;
 - (2) Held primarily for trading purposes;
 - (3) Expected to be realized within twelve months after the reporting period; or
 - (4) Cash or cash equivalents, unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.Assets that do not meet the above criteria are classified as non-current assets.
2. **Liabilities** are classified as current liabilities if they meet any of the following criteria:
 - (1) Expected to be settled in the normal operating cycle;
 - (2) Held primarily for trading purposes;
 - (3) Due to be settled within twelve months after the reporting period; or
 - (4) The Group does not have an unconditional right to defer settlement of the liability for at least twelve months after the reporting period.Liabilities that do not meet the above criteria are classified as non-current liabilities.

(6) Cash equivalents

Cash equivalents are short-term, highly liquid investments that are readily convertible to known amounts of cash and subject to an insignificant risk of changes in value. Time deposits that meet the above definition and are held for the purpose of meeting short-term cash commitments are classified as cash equivalents.

V. Significant Accounting Judgments, Estimates and Assumptions

Uncertainty

In preparing these consolidated financial statements, management has exercised judgment in determining the accounting policies applied and has made accounting estimates and assumptions based on reasonable expectations of future events at the balance sheet date. Actual results may differ from these estimates and assumptions. The estimates and assumptions are continuously reviewed, taking into account historical experience and other factors. Such estimates and assumptions may result in adjustments to the carrying amounts of assets and liabilities in the next financial year. Details are as follows:

(1) Significant judgments in applying accounting policies

Management has assessed that there is no significant uncertainty relating to significant judgments in applying the Group's accounting policies.

(2) Key sources of estimation uncertainty

1. Estimation of the stage of completion of service revenue

The Group's principal revenue is derived from providing genetic testing and medical testing services, including preconception, prenatal and neonatal testing services. Such service revenue is recognized based on the stage of completion, which is measured by the proportion of actual service days incurred to the estimated total service days, multiplied by the contract consideration. The estimated total service days are determined based on historical experience and are adjusted when factors such as improvements in R&D capabilities or equipment upgrades result in changes to the estimated total service days.

2. Valuation of inventories

Inventories are stated at the lower of cost and net realizable value. Accordingly, the Group applies judgment and estimates in determining the net realizable value of inventories at the balance sheet date. Due to rapid technological changes, the Group assesses the amounts of inventories that may be subject to normal loss, obsolescence, or having no market value and writes down inventory cost to net realizable value. The valuation is primarily based on recent selling prices and estimated product demand in specific future periods and therefore may be subject to significant changes.

VI. Description of Significant Accounts

(1) Cash and cash equivalents

	September 30, 2025	December 31, 2024	September 30, 2024
Cash on hand	\$381	\$322	\$328
Checking accounts and demand deposits	33,756	69,357	59,355
Time deposits	42,400	42,400	42,400

	September 30, 2025	December 31, 2024	September 30, 2024
Total	\$76,537	\$112,079	\$102,083

1. The Group maintains cash and cash equivalents with reputable financial institutions. In addition, the Group deals with multiple financial institutions to diversify credit risk. The likelihood of default is expected to be low.
2. The Group did not pledge any cash and cash equivalents as collateral.
3. The Group reclassified time deposits with maturities of more than three months and up to one year to financial assets at amortized cost - current. The balances as of September 30, 2025, December 31, 2024 and September 30, 2024 were \$34,100, \$34,100 and \$34,100, respectively. For interest income on time deposits recognized for the three months and nine months ended September 30, 2025 and 2024, please refer to Note VI(15). The Group did not pledge any financial assets at amortized cost - current as collateral.

(2) Notes and accounts receivable

	September 30, 2025	December 31, 2024	September 30, 2024
Notes receivable	\$1,846	\$2,508	\$3,109
Accounts receivable	52,428	51,451	54,992
Accounts receivable - related parties	2,048	2,590	2,814
Subtotal	54,476	54,041	57,806

	Septemb er 30, 2025	Decemb er 31, 2024	Septemb er 30, 2024
Less: allowanc e for expected credit losses	(19)	(20)	(24)
Total	\$54,457	\$54,021	\$57,782

1. Aging analysis of notes and accounts receivable (including related parties) and relevant credit risk information are disclosed in Note XII(2).
2. The balances of notes and accounts receivable as of **September 30, 2025, December 31, 2024, September 30, 2024 and January 1, 2024** all arose from contracts with customers. In addition, the balance of notes and accounts receivable arising from contracts with customers as of **January 1, 2024** was **\$71,806**.
3. The Group did not hold any collateral for the above notes and accounts receivable.

(3) Inventories

September 30, 2025

	Cost	Allowanc e for inventor y valuatio n losses	Carryin g amount
Raw material s	\$49,651	(\$4,487)	\$45,164

December 31, 2024

	Cost	Allowance for inventory valuation losses	Carrying amount
Raw materials	\$51,411	(\$5,014)	\$46,397
September 30, 2024			

	Cost	Allowance for inventory valuation losses	Carrying amount
Raw materials	\$55,694	(\$4,333)	\$51,361

1. The above inventories were not pledged as collateral.
2. Inventory-related expenses recognized for the period:

For the three months ended September 30

	2025	2024
Consumption of raw materials	\$34,895	\$37,914
Raw materials reclassified to expenses	2,410	1,530
Inventory valuation losses	296	1,321
Total	\$37,601	\$40,765

For the nine months ended September 30

	2025	2024
Consumption of raw materials	\$116,824	\$121,434
Raw materials reclassified to expenses	7,222	6,079

	2025	2024
Inventory valuation losses (reversal)	(527)	1,069
Total	\$123,519	\$128,582

The Group recognized a reversal of inventory valuation losses due to the consumption of inventories for which allowances had previously been provided, resulting in a decrease in the allowance for inventory valuation losses.

(4) Investments accounted for using the equity method

	September 30, 2025		December 31, 2024		September 30, 2024	
Associates	Carrying amount	Ownership %	Carrying amount	Ownership %	Carrying amount	Ownership %
Ho-Sin Corporation	\$381,176	16.56%	\$368,015	16.56%	\$361,553	16.56%

Share of profit (loss) of associates accounted for using the equity method:

	Three months ended Sep. 30, 2025	Three months ended Sep. 30, 2024
Ho-Sin Corporation	\$5,951	\$6,573
	Nine months ended Sep. 30, 2025	Nine months ended Sep. 30, 2024
Ho-Sin Corporation	\$19,091	\$19,391

The investment in Ho-Sin Corporation as of September 30, 2025 and September 30, 2024 was measured and recognized based on the investee's self-prepared financial statements, which were not reviewed by independent auditors.

1. Associates

(1) Basic information of the Group's material associate

Associate	Principal place of business	Ownership % as of Sep. 30, 2025	Dec. 31, 2024	Sep. 30, 2024	Nature of relationship	Measurement method
Ho-Sin Corporation	Taiwan	16.56%	16.56%	16.56%	Associate	Equity method

(2) Summarized financial information of the Group's material associate

A. Balance sheet

	Sep. 30, 2025	Dec. 31, 2024	Sep. 30, 2024
Current assets	\$1,148,669	\$570,509	\$1,016,060
Non-current assets	4,010,683	4,498,917	4,040,824
Current liabilities	(964,139)	(540,837)	(971,132)
Non-current liabilities	(1,890,983)	(2,306,277)	(1,902,462)
Net assets	\$2,304,230	\$2,222,312	\$2,183,290

	Sep. 30, 2025	Dec. 31, 2024	Sep. 30, 2024
Group's share of net assets	\$381,176	\$368,015	\$361,553
Carrying amount of investment in associate	\$381,176	\$368,015	\$361,553

B. Statement of comprehensive income

For the three months ended September 30

	2025	2024
Revenue	\$196,761	\$204,846
Profit (loss) for the period from continuing operations	\$35,934	\$39,692
Total comprehensive income	\$35,934	\$39,692
Dividends received from associate	\$-	\$-

For the nine months ended September 30

	2025	2024
Revenue	\$684,192	\$568,017
Profit (loss) for the period from continuing operations	\$115,274	\$117,084
Total comprehensive income	\$115,274	\$117,084
Dividends received from associate	\$5,930	\$5,930

2. The Group's associates do not have quoted market prices; therefore, fair value information is not available.
-

(5) Property, plant and equipment

2025

	Machinery and equipment	Vehicles	Office equipment	Leasehold improvements	Others	Total
Cost						
Balance at Jan. 1	\$134,082	\$8,508	\$24,890	\$28,149	\$21,210	\$216,839
Additions	-	-	-	-	1,251	1,251
Disposals	(39)	-	(5)	-	-	(44)
Balance at Sep. 30	\$113,424	\$8,508	\$24,880	\$28,018	\$22,408	\$197,238
Accumulated depreciation						
Balance at Jan. 1	(92,627)	(8,508)	(23,207)	(18,515)	(20,822)	(163,679)
Depreciation expense	(10,158)	-	(1,374)	(2,011)	(223)	(13,766)
Balance at Sep. 30	(82,166)	(8,508)	(24,576)	(20,395)	(20,992)	(156,637)
Carrying amount at Sep. 30	\$31,258	\$-	\$304	\$7,623	\$1,416	\$40,601

2024

	Machinery and equipment	Vehicles	Office equipment	Leasehold improvements	Others	Total
Cost						
Balance at Jan. 1	\$123,771	\$8,508	\$25,150	\$28,333	\$21,669	\$207,431
Additions	16,204	-	114	-	378	16,696
Balance at Sep. 30	\$136,397	\$8,508	\$25,329	\$28,240	\$21,468	\$219,942
Accumulated depreciation						
Balance at Jan. 1	(85,670)	(8,150)	(20,483)	(15,921)	(21,299)	(151,523)
Depreciation expense	(9,495)	(358)	(2,507)	(2,107)	(268)	(14,735)
Balance at Sep. 30	(91,587)	(8,508)	(23,055)	(17,935)	(20,988)	(162,073)
Carrying amount at Sep. 30	\$44,810	\$-	\$2,274	\$10,305	\$480	\$57,869

The Group did not pledge any property, plant and equipment as collateral, and no borrowing costs were capitalized.

(6) Leases – lessee

1. The Group leases office premises and vehicles. The lease terms range from **1 to 10 years**. Lease contracts are negotiated on an individual basis and contain a variety of different terms and conditions, and do not impose any other restrictions.
2. Carrying amounts of right-of-use assets and depreciation expense

2025

	Office premises	Vehicles	Total
Balance at Jan. 1	\$48,883	\$1,113	\$49,996
Early termination	(2,571)	-	(2,571)
Depreciation expense	(11,146)	(476)	(11,622)
Balance at Sep. 30	\$35,166	\$637	\$35,803

2024

	Office premises	Vehicles	Total
Balance at Jan. 1	\$58,426	\$1,748	\$60,174
Additions	5,606	-	5,606
Depreciation expense	(11,278)	(477)	(11,755)
Balance at Sep. 30	\$52,754	\$1,271	\$54,025

3. Amounts recognized in profit or loss relating to lease contracts

For the three months ended September 30

Items affecting profit or loss	2025	2024
Interest expense on lease liabilities	\$187	\$273
Expenses relating to short-term leases	151	142
Gain (loss) on lease modifications	(31)	-
Total	\$307	\$415

For the nine months ended September 30

Items affecting profit or loss	2025	2024
Interest expense on lease liabilities	\$636	\$812
Expenses relating to short-term leases	427	409
Gain (loss) on lease modifications	(31)	-
Total	\$1,032	\$1,221

4. In addition to the cash outflows for lease-related expenses described in Note VI(6)3, principal repayments of lease liabilities for the nine months ended September 30, 2025 and 2024 are disclosed in Note VI(22).

(7) Other payables

	September 30, 2025	December 31, 2024	September 30, 2024
Accrued payroll	\$18,992	\$26,969	\$24,883
Royalties payable	1,708	2,076	2,481
Service fees payable	2,054	2,999	2,202
Payables for equipment	893	1,289	-
Others	6,681	7,440	7,097
Total	\$30,328	\$40,773	\$36,663

(8) Provisions

2025

	Asset retirement obligations	Provision for compensation	Total
Balance at Jan. 1	\$3,030	\$1,060	\$4,090
Reversal of provisions	-	(344)	(344)
Interest accretion	34	-	34
Balance at Sep. 30	\$3,064	\$716	\$3,780

2024

	Asset retirement obligations	Provision for compensation	Total
Balance at Jan. 1	\$3,165	\$2,465	\$5,630
Additions	-	29	29

	Asset retirement obligations	Provision for compensation	Total
Utilization	-	(1,350)	(1,350)
Reversal of provisions	(197)	-	(197)
Interest accretion	34	-	34
Net foreign exchange differences	17	-	17
Balance at Sep. 30	\$3,019	\$1,144	\$4,163

Analysis of provisions

	September 30, 2025	December 31, 2024	September 30, 2024
Current	\$716	\$1,060	\$1,144
Non-current	3,064	3,030	3,019
Total	\$3,780	\$4,090	\$4,163

1. Provision for compensation

The Group recognizes provisions relating to compensation in connection with testing services based on historical experience and relevant statistical data.

2. Asset retirement obligations

Under the relevant lease contracts, the Group is obligated to dismantle, remove, or restore leased office premises. Accordingly, provisions are recognized at the present value of the expected costs to dismantle, remove, or restore the premises. The Group expects such obligations to be settled upon expiry of the lease terms.

2025

	Office premis es	Vehicl es	Total
Balance at Jan. 1	\$48,883	\$1,113	\$49,996
Early terminatio n	(2,571)	-	(2,571)
Depreciati on expense	(11,146)	(476)	(11,622)
Balance at	\$35,16	\$637	\$35,80

	Office premises	Vehicles	Total
Sep. 30 2024	6		3
	Office premises	Vehicles	Total
Balance at Jan. 1	\$58,426	\$1,748	\$60,174
Additions	5,606	–	5,606
Depreciation expense	(11,278)	(477)	(11,755)
Balance at Sep. 30	\$52,754	\$1,271	\$54,025

3. Amounts recognized in profit or loss relating to lease contracts

For the three months ended September 30

Items affecting profit or loss	2025	2024
Interest expense on lease liabilities	\$187	\$273
Expenses relating to short-term leases	151	142
Gain (loss) on lease modifications	(31)	–
Total	\$307	\$415

For the nine months ended September 30

Items affecting profit or loss	2025	2024
Interest expense on lease liabilities	\$636	\$812
Expenses relating to short-term leases	427	409
Gain (loss) on lease modifications	(31)	–

Items affecting profit or loss	2025	2024
Total	\$1,032	\$1,221

4. In addition to the cash outflows for lease-related expenses described in Note VI(6)3, principal repayments of lease liabilities for the nine months ended September 30, 2025 and 2024 are disclosed in Note VI(22).

(7) Other payables

	September 30, 2025	December 31, 2024	September 30, 2024
Accrued payroll	\$18,992	\$26,969	\$24,883
Royalties payable	1,708	2,076	2,481
Service fees payable	2,054	2,999	2,202
Payables for equipment	893	1,289	–
Others	6,681	7,440	7,097
Total	\$30,328	\$40,773	\$36,663

(8) Provisions

2025

	Asset retireme nt obligati ons	Provision for compensat ion	Tota l
Balance at Jan. 1	\$3, 030	\$1, 060	\$4, 0 90
Reversal of provisio ns	—	(344)	(344)
Interest accretio n	34	—	34
Balance at Sep. 30	\$3, 064	\$716	\$3, 7 80

2024

	Asset retireme nt obligati ons	Provision for compensat ion	Tota l
Balance at Jan. 1	\$3, 165	\$2, 465	\$5, 6 30
Addition s	—	29	29
Utilizat ion	—	(1, 350)	(1, 3 50)
Reversal of provisio ns	(197)	—	(197)
Interest accretio	34	—	34

	Asset retirement obligations	Provision for compensation	Total
n			
Net foreign exchange differences	17	–	17
Balance at Sep. 30	\$3,019	\$1,144	\$4,163
Analysis of provisions			
	September 30, 2025	December 31, 2024	September 30, 2024
Current	\$716	\$1,060	\$1,144
Non- current	3,064	3,030	3,019
Total	\$3,780	\$4,090	\$4,163

1. Provision for compensation

The Group recognizes provisions relating to compensation in connection with testing services based on historical experience and relevant statistical data.

2. Asset retirement obligations

Under the relevant lease contracts, the Group is obligated to dismantle, remove, or restore leased office premises. Accordingly, provisions are recognized at the present value of the expected costs to dismantle, remove, or restore the premises. The Group expects such obligations to be settled upon expiry of the lease terms.

(9) Pension plans

The Company has established a **defined contribution pension plan** in accordance with the *Labor Pension Act* for employees who are Taiwanese nationals. Under this plan, the Company contributes **6% of employees' monthly salaries** to individual pension accounts maintained by the Bureau of Labor Insurance. Employees are entitled to receive pension benefits either in the form of monthly payments or lump-sum payments based on the amounts accumulated in their individual pension accounts and related investment returns.

For the three months and nine months ended September 30, 2025 and 2024, pension costs recognized by the Company amounted to \$1,205, \$1,236, \$3,766 and \$3,631, respectively.

(10) Share-based payments

1. Share-based payment arrangements of the Company

Type of arrangement	Grant date	Number of options granted (shares)	Contract period	Vesting conditions	Settlement
Second employee stock option plan	May 13, 2020	770,000	5 years	20% vested after 2 years; cumulative 50% vested after 3 years; cumulative 100% vested after 4 years	Equity-settled
Second employee stock option plan	March 24, 2021	230,000	5 years	20% vested after 2 years; cumulative 50% vested after 3 years; cumulative 100% vested after 4 years	Equity-settled

2. Details of the share-based payment arrangements

(1) Second employee stock option plan (grant date: May 13, 2020)

	2025		2024	
	Number of options	Weighted-average exercise price (NT\$)	Number of options	Weighted-average exercise price (NT\$)
Outstanding at January 1	378,000	52.6	605,000	52.8
Forfeited during the period	-	-	(10,000)	52.8
Exercised during the period	-	-	(217,000)	52.7
Expired during the period	(378,000)	52.6	-	-

	2025		2024	
Outstanding at September 30	-	-	378,000	52.6
Exercisable at September 30	-	-	378,000	52.6

(2) Second employee stock option plan (grant date: March 24, 2021)

	2025		2024	
	Number of options	Weighted-average exercise price (NT\$)	Number of options	Weighted-average exercise price (NT\$)
Outstanding at January 1	31,000	45.1	195,000	45.2
Forfeited during the period	-	-	(150,000)	45.2
Exercised during the period	-	-	(14,000)	45.2
Outstanding at September 30	31,000	44.7	31,000	45.1
Exercisable at September 30	31,000	44.7	8,500	45.1

Note: Exercise prices were adjusted in accordance with the Company's employee stock option plan.

3. Outstanding options as of the balance sheet date

Plan	Grant date	Expiry date	Sep. 30, 2025 (thousand shares)	Exercise price	Dec. 31, 2024 (thousand shares)	Exercise price	Sep. 30, 2024 (thousand shares)	Exercise price
Second employee stock option plan	May 13, 2020	May 12, 2025	-	-	378.0	52.6	378.0	52.6
Second employee stock option plan	March 24, 2021	March 23, 2026	31.0	44.7	31.0	45.1	31.0	45.1

4. Fair value of stock options

The fair value of stock options granted was estimated using the **Black-Scholes option pricing model**, with the following assumptions:

Expected volatility was estimated based on historical share price volatility over a period commensurate with the expected life of the options.

5. Share-based payment expenses

For the three months and nine months ended September 30, 2025 and 2024, share-based payment expenses recognized amounted to **\$0, \$15, (\$5) and (\$742)**, respectively.

(11) Share capital

1. As of September 30, 2025, the Company's authorized share capital amounted to **\$300,000**, divided into **30,000 thousand shares** (including **2,000 thousand shares** reserved for employee stock options). Paid-in capital amounted to **\$215,934**, with a par value of **NT\$10 per share**. All issued shares were fully paid.

The numbers of issued shares outstanding during the periods were as follows:

	2025 (shares)	2024 (shares)
Balance at January 1	21,593,400	21,362,400
Exercise of employee stock options -		231,000
Balance at September 30	21,593,400	21,593,400

2. For the nine months ended September 30, 2025 and 2024, the Company issued **0 shares and 231,000 shares**, respectively, as a result of employee stock option exercises. All related registration procedures were completed.
-

(12) Capital surplus

1. In accordance with the *Company Act*, capital surplus arising from share premiums and donations received may be used to offset accumulated deficits. When there is no accumulated deficit, such capital surplus may be distributed as new shares or cash dividends in proportion to shareholders' shareholdings. In accordance with the *Securities and Exchange Act*, the amount of capital surplus

capitalized in any year shall not exceed **10% of paid-in capital**. Capital surplus may not be used to cover capital losses unless retained earnings are insufficient.

2. Movements in capital surplus are disclosed in the **Consolidated Statements of Changes in Equity**.

(13) Retained earnings

1. According to the Company's Articles of Incorporation, if there is no profit for a fiscal year, no dividends or bonuses shall be distributed. If there is profit, the Company shall first pay taxes, offset accumulated deficits, and then appropriate **10%** of the remaining balance as **legal reserve**, unless the accumulated legal reserve has reached the Company's paid-in capital. Thereafter, **special reserve** shall be appropriated or reversed in accordance with applicable laws and regulations. The remaining balance, together with accumulated undistributed earnings from prior years, constitutes **distributable earnings**, which shall be proposed by the Board of Directors for shareholders' approval.

The total amount of dividends distributed to shareholders in any year shall not be less than **30%** of the distributable earnings for that year. When accumulated undistributed earnings are less than **1% of paid-in capital**, distribution may be waived. Dividends may be distributed in the form of cash dividends or stock dividends. Given the Company's stable operations, **cash dividends are given priority**, and if stock dividends are distributed, cash dividends shall not be less than **30%** of total dividends.

Pursuant to Article 240, paragraph 5 of the Company Act, the Board of Directors is authorized to resolve, with approval by two-thirds of directors present and a majority of those present, to distribute dividends and bonuses, or legal reserve and capital surplus as cash dividends, and report such resolution to the shareholders' meeting.

2. Legal reserve may not be used except to offset deficits or to issue new shares or distribute cash dividends in proportion to shareholders' shareholdings, provided that the portion distributed shall be limited to the excess over **25% of paid-in capital**.
3. In accordance with regulations, when other equity items have debit balances at the balance sheet date, the Company shall appropriate special reserve before distributing earnings. When such debit balances are subsequently reversed, the reversed amounts may be included in distributable earnings.
4. Distribution of earnings

The earnings distributions approved by shareholders' meetings on **June 4, 2025** and **May 29, 2024** for fiscal years **2024** and **2023**, respectively, were as follows:

	FY2024	FY2023
	Amount Per share (NT\$)	Amount Per share (NT\$)
Legal reserve	\$1,843	\$1,153

	FY2024		FY2023
Special reserve	102		14
Cash dividends	6,478 0.3		4,272 0.2
Total	\$8,423		\$5,439

(14) Revenue

1. Disaggregation of revenue from contracts with customers

The Group's revenue arises from services transferred **over time** and is disaggregated by major product lines and geographical regions as follows:

For the three months ended September 30, 2025

	Testing services (Taiwan)	Other services	Others	Total
Revenue from contracts with customers	\$89,554	\$3,853	\$4	\$93,411

For the three months ended September 30, 2024

	Testing services (Taiwan)	Other services	Others	Total
Revenue from contracts with customers	\$101,635	\$4,583	\$31	\$106,249

For the nine months ended September 30, 2025

	Testing services (Taiwan)	Other services	Others	Total
Revenue from contracts with customers	\$277,427	\$12,548	\$38	\$290,013

For the nine months ended September 30, 2024

	Testing services (Taiwan)	Other services	Others	Total
Revenue from contracts with customers	\$335,551	\$14,212	\$79	\$349,842

2. Contract assets and contract liabilities

(1) Contract assets and contract liabilities recognized from revenue contracts

	Sep. 30, 2025	Dec. 31, 2024	Sep. 30, 2024	Jan. 1, 2024
Contract assets – current	\$5,894	\$9,410	\$9,317	\$4,159

	Sep. 30, 2025	Dec. 31, 2024	Sep. 30, 2024	Jan. 1, 2024
Contract liabilities – current	798	1,773	2,175	773

(2) Revenue recognized from contract liabilities at the beginning of the period

	Three months ended Sep. 30		Nine months ended Sep. 30	
	2025	2024	2025	2024
Testing-related services	\$885	\$-	\$1,411	\$696

(15) Interest income

For the three months ended September 30

	2025	2024
Interest income from bank deposits	\$250	\$242
Imputed interest income on leases	2	3
Total	\$252	\$245

For the nine months ended September 30

	2025	2024
Interest income from bank deposits	\$923	\$916
Imputed interest income on leases	77	72
Total	\$1,000	\$988

(16) Finance costs

For the three months ended September 30

	2025	2024
Interest expense on lease liabilities	\$187	\$273
Interest expense on asset retirement obligations	10	11
Total	\$197	\$284

For the nine months ended September 30

	2025	2024
Interest expense on lease liabilities	\$636	\$812
Interest expense on asset retirement obligations	34	34
Total	\$670	\$846

(17) Additional information on expenses by nature

For the three months ended September 30

	2025	2024
Employee benefit expenses	\$25,921	\$33,790
Depreciation of property, plant and equipment and right-of-use assets	7,894	8,859
Amortization of intangible assets	2,323	1,761

For the nine months ended September 30

	2025	2024
Employee benefit expenses	\$92,685	\$95,884
Depreciation of property, plant and equipment and right-of-use assets	25,388	26,490
Amortization of intangible assets	6,474	4,646

(18) Employee benefit expenses

Employee benefit expenses for the three months and nine months ended September 30, 2025 and 2024 are summarized in the tables above.

For the nine months ended September 30, 2025, the Group incurred a loss; therefore, no employee or director remuneration was accrued.

(19) Income tax

1. Income tax (benefit) expense

The components of income tax (benefit) expense for the three months and nine months ended September 30, 2025 and 2024 are presented in the tables above.

2. Income taxes relating to other comprehensive income

Income taxes relating to foreign currency translation differences are disclosed in the tables above.

3. The Group did not recognize any income taxes directly charged or credited to equity for the periods presented.
4. The Company's income tax returns have been assessed by the tax authorities through fiscal year **2023**. The subsidiary, Chun-Chih Genomics Co., Ltd., has also been assessed through fiscal year **2023**.

(20) Earnings (loss) per share

Basic and diluted earnings (loss) per share for the three months and nine months ended September 30, 2025 and 2024 were calculated based on the weighted-average number of ordinary shares outstanding, as disclosed in the tables above.

Anti-dilutive potential ordinary shares were excluded from the calculation.

(21) Supplemental cash flow information

Only part of the investing activities were paid in cash:

- Acquisition of right-of-use assets
- Acquisition of property, plant and equipment
- Acquisition of intangible assets

The related reconciliations between cash payments and total additions are disclosed in the tables above.

(22) Changes in liabilities arising from financing activities

The changes in liabilities arising from financing activities for the nine months ended September 30, 2025 and 2024 are summarized in the tables above, including **dividends payable** and **lease liabilities (current and non-current)**.

VII. Related Party Transactions

(1) Names of Related Parties and Relationships

Name of Related Party	Relationship with the Group
Hsin-Yi Co., Ltd.	Associate
Hsin-Yun Co., Ltd.	The Chairman of the Company serves as a director
Hsin-Yi Obstetrics and Gynecology Clinic (Hua-Ning)	The Chairman of the Company is the responsible person
Sofiva Medical Laboratory	Substantive related party
Heping Obstetrics and Gynecology Clinic	Substantive related party
All directors, the general manager and key management personnel	Key management personnel and governance bodies of the Group

(2) Significant Transactions with Related Parties

1. Transactions for Testing Services

(1) Service Revenue

Details of service revenue generated from providing testing services to related parties are as follows:

For the three months ended September 30

	2025	2024
Other related parties	\$3,609	\$4,972

For the nine months ended September 30

	2025	2024
Other related parties	\$11,876	\$17,519

The testing services provided to related parties are **not different from those provided to general customers**. Transaction prices are determined based on mutual agreements. The collection terms do not significantly differ from those of non-related parties. The collection period for general customers ranges from **advance receipts to monthly settlement within 90 days**, while the collection period for the above related parties is approximately **60 days after month-end**.

(2) Accounts Receivable

Balances of accounts receivable arising from the above related party transactions are as follows:

	September 30, 2025	December 31, 2024	September 30, 2024
Other related parties	\$2,048	\$2,590	\$2,814

(3) Contract Assets

Balances of contract assets arising from the above related party transactions are as follows:

	September 30, 2025	December 31, 2024	September 30, 2024
Other related parties	\$264	\$352	\$432

2. Outsourced Testing Transactions

(1) Service Costs

Details of service costs incurred from testing services provided by related parties are as follows:

For the three months ended September 30

	2025	2024
Other related parties – Sofiva Medical Laboratory	\$4,005	\$5,371
Other related parties – Others	638	978
Total	\$4,643	\$6,349

For the nine months ended September 30

	2025	2024
Other related parties – Sofiva Medical Laboratory	\$12,983	\$19,565
Other related parties – Others	1,722	2,939
Total	\$14,705	\$22,504

The transaction prices for testing services provided by related parties are determined based on mutual agreements. The payment terms do not significantly differ from those of non-related parties. The payment period for general suppliers is **60 days after month-end**, which is the same as that for the above related parties.

(2) Accounts Payable

Balances of accounts payable arising from the above related party transactions are as follows:

	September 30, 2025	December 31, 2024	September 30, 2024
Other related parties – Sofiva Medical Laboratory	\$2,554	\$2,836	\$3,304
Other related parties – Others	379	380	681
Total	\$2,933	\$3,216	\$3,985

3. Investment Transactions

(1) Dividend Income

Dividend income arising from investments in associates (presented as a deduction from investments accounted for using the equity method) is described in **Note 6(4)**.

(2) Other Receivables

As of **September 30, 2025**, **December 31, 2024**, and **September 30, 2024**, balances of other receivables arising from the above related party transactions were **\$0**.

4. Other Transactions – Operating Expenses / Other Payables

For the three-month and nine-month periods ended **September 30, 2025** and **2024**, expenses incurred for planning and consulting services provided by associates amounted to **\$270**, **\$150**, **\$570**, and **\$450**, respectively. Balances of other payables related to such transactions as of **September 30, 2025**, **December 31, 2024**, and **September 30, 2024** were **\$95**, **\$52**, and **\$105**, respectively.

(3) Compensation of Key Management Personnel

For the three months ended September 30

	2025	2024
Short-term employee benefits	\$3,634	\$3,811
Post-employment benefits	50	50

	2025	2024
Total	\$3,684	\$3,861

For the nine months ended September 30

	2025	2024
Short-term employee benefits	\$11,754	\$11,761
Post-employment benefits	152	152
Share-based payments	–	106
Total	\$11,906	\$12,019

VIII. Pledged assets

None.

IX. Significant contingent liabilities and unrecognized contractual commitments

(1) Significant contingent liabilities

None.

(2) Significant unrecognized contractual commitments

The Group is authorized to use certain testing technologies and is required to pay royalties **quarterly based on the number of testing reports issued.**

X. Significant disaster losses

None.

XI. Significant subsequent events

None.

XII. Other disclosures

(1) Capital management

The Group's objectives when managing capital are to safeguard the Group's ability to continue as a going concern, maintain an optimal capital structure to reduce the cost of capital, and provide returns to shareholders. In order to maintain or adjust the capital structure, the Group may adjust dividend payments to shareholders, return capital to shareholders, issue new shares, or sell assets to reduce debt.

The Group monitors capital using the **debt-to-asset ratio**, which is calculated as total liabilities divided by total assets. The Group's capital management strategy in 2025 remained consistent with that in 2024. The Group's debt-to-asset ratios as of September 30, 2025, December 31, 2024 and September 30, 2024 are disclosed in the **Consolidated Statements of Financial Position**.

(2) Financial instruments

1. Categories of financial instruments

Details of the Group's financial assets and financial liabilities are disclosed in **Note VI** and the **Consolidated Statements of Financial Position**.

2. Risk management policies

The Group's activities expose it to various financial risks, including **market risk** (foreign exchange risk, price risk and interest rate risk), **credit risk**, and **liquidity risk**. Risk management is carried out by the Group's finance department in accordance with policies approved by management.

3. Nature and extent of significant financial risks

XII. Other disclosures

(2) Financial instruments

3. Nature and extent of significant financial risks

(1) Market risk

A. Foreign exchange risk

The Group operates internationally and is exposed to foreign exchange risk arising from various currency exposures, primarily with respect to the **Thai Baht (“THB”)** and **United States Dollar (“USD”)**. The Company’s functional currency is the **New Taiwan Dollar (“NTD”)**, while the functional currencies of its subsidiaries are **NTD and THB**.

Significant foreign currency – denominated monetary assets and liabilities exposed to foreign exchange risk are as follows:

Foreign currency exposure table

(Please refer to the table presented in the Chinese version. Amounts and exchange rates remain unchanged.)

The total exchange (losses) gains, including realized and unrealized, arising from significant foreign currency fluctuations recognized for the three months and nine months ended September 30, 2025 and 2024 amounted to **\$328, \$1,016, (\$474) and \$785**, respectively.

Sensitivity analysis – foreign exchange risk

The following table illustrates the impact on profit or loss and other comprehensive income if foreign currencies had appreciated or depreciated by **1%** against the functional currency, with all other variables held constant.

Foreign exchange sensitivity analysis table

(Please refer to the table presented in the Chinese version.)

B. Price risk

The Group is **not exposed to significant price risk**, as it does not hold material equity instruments or commodities subject to market price fluctuations.

C. Cash flow and fair value interest rate risk

The Group's transactions **do not expose it to significant interest rate risk**, as the Group does not have material interest-bearing financial assets or liabilities with floating interest rates.

(2) Credit risk

Credit risk refers to the risk that a counterparty will default on its contractual obligations, resulting in financial loss to the Group. The Group's credit risk arises primarily from **cash and cash equivalents held with banks**, and from **contract assets, notes receivable and accounts receivable**.

A. Credit risk management

The Group has established internal credit policies. Before entering into transactions with new customers, the Group evaluates and manages credit risk by considering customers' **financial condition, historical experience, and other relevant factors**.

Credit limits are set by the finance department based on internal or external credit ratings and are monitored on a regular basis.

B. Group-wide credit risk management

Credit risk is managed on a **group-wide basis**. Each operating entity evaluates credit risk prior to setting payment and delivery terms. Management determines individual risk limits and monitors utilization on a periodic basis.

C. Definition of credit deterioration and default

The Group considers that **credit risk has increased significantly** when contractual payments are overdue by more than **90 days** from the agreed payment terms.

Financial assets are considered to be **in default** when contractual payments are overdue by more than **360 days**.

D. Expected credit loss – simplified approach

The Group applies the **simplified approach** to measure expected credit losses for **notes receivable, accounts receivable (including related parties) and contract assets**, using a **provision matrix** based on historical credit loss experience, adjusted for forward-looking information.

E. Recovery and write-off policy

For financial assets that have defaulted, the Group continues to pursue recovery through legal procedures. Amounts that are **not reasonably expected to be recovered** are written off.

F. Provision matrix

The following tables present the aging analysis and expected credit loss rates based on days past due:

Provision matrix tables (by aging)

- As of September 30, 2025
- As of December 31, 2024
- As of September 30, 2024

(Amounts, expected loss rates, and classifications remain exactly the same as in the Chinese version.)

G. Movement in allowance for expected credit losses

Movements in the allowance for expected credit losses for notes receivable, accounts receivable and contract assets under the simplified approach are as follows:

Allowance for ECL movement table

(Same figures as Chinese version.)

(3) Liquidity risk

Liquidity risk refers to the risk that the Group may not be able to meet its obligations when they fall due.

A. Cash flow forecasting

The Group's finance department performs cash flow forecasts to ensure sufficient liquidity to meet operational needs and to maintain adequate unused borrowing capacity at all times.

B. Management of surplus cash

Surplus cash beyond operating requirements is invested in **interest-bearing demand deposits** with sufficient liquidity to meet forecasted cash needs.

C. Undrawn borrowing facilities

As of **September 30, 2025, December 31, 2024 and September 30, 2024**, the Group had **no unused borrowing facilities**.

D. Maturity analysis of financial liabilities

The table below analyzes the Group's non-derivative financial liabilities into relevant maturity groupings based on the remaining contractual maturities. The amounts disclosed are **undiscounted contractual cash flows**.

Maturity analysis table – lease liabilities

- As of September 30, 2025
- As of December 31, 2024
- As of September 30, 2024

(Amounts and maturities are identical to the Chinese version.)

(3) Fair value information

The Group does not have significant financial instruments measured at fair value. The valuation techniques used to estimate fair value **do not have a material impact** on the Group.

For financial instruments not measured at fair value, including **cash and cash equivalents, financial assets measured at amortized cost, contract assets, notes receivable, accounts receivable (including related parties), refundable deposits, accounts payable (including related parties), other payables and lease liabilities**, the carrying amounts are **reasonable approximations** of their fair values.

XIII. Additional disclosures

(1) Information on significant transactions

1. Loans to others: refer to **Table 1**.
2. Endorsements and guarantees: None.
3. Marketable securities held at period end: None.
4. Purchases or sales with related parties exceeding NT\$100 million or 20% of paid-in capital: None.
5. Receivables from related parties exceeding NT\$100 million or 20% of paid-in capital: None.
6. Intercompany relationships and significant transactions: refer to **Table 2**.

(2) Information on investees

Refer to **Table 3**.

(3) Information on investments in Mainland China

None.

XIV. Segment information

(1) General information

The Group operates in a single industry. Management evaluates performance and allocates resources on a **group-wide basis**, and therefore the Group has **only one reportable operating segment**.

(2) Measurement of segment information

Segment profit or loss is measured on a **pre-tax basis**, consistent with performance evaluation.

(3) Segment profit or loss, assets and liabilities

As the Group has only one reportable segment, segment information is consistent with amounts presented in the **Consolidated Statements of Comprehensive Income** and the **Consolidated Statements of Financial Position**.

(4) Reconciliation information

No reconciliation is required as the Group has only one reportable segment.